Stock HALO HALOZYME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Halozyme Therapeutics, Inc.

Equities

HALO

US40637H1095

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
43.08 USD -1.69% Intraday chart for Halozyme Therapeutics, Inc. -5.40% +16.56%
May. 22 Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing MT
May. 07 Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,591 5,765 5,659 7,694 4,882 5,577 - -
Enterprise Value (EV) 1 2,874 6,014 5,794 8,837 6,046 6,477 5,999 5,854
P/E ratio -35.5 x 46.9 x 14.7 x 39.5 x 17.6 x 14.5 x 11.4 x 8.29 x
Yield - - - - - - - -
Capitalization / Revenue 13.2 x 21.5 x 12.8 x 11.7 x 5.89 x 5.87 x 5.08 x 4.26 x
EV / Revenue 14.7 x 22.5 x 13.1 x 13.4 x 7.29 x 6.81 x 5.47 x 4.47 x
EV / EBITDA -45.2 x 40.8 x 20.8 x 28.1 x 14.2 x 11.7 x 8.71 x 7.03 x
EV / FCF -32.1 x 114 x 19.4 x 37.6 x - 13.8 x 10.1 x -
FCF Yield -3.11% 0.88% 5.14% 2.66% - 7.27% 9.93% -
Price to Book 26.4 x 38.2 x 28.1 x 45.3 x - 9.84 x 5.55 x 4.4 x
Nbr of stocks (in thousands) 146,142 134,972 140,725 135,213 132,098 127,274 - -
Reference price 2 17.73 42.71 40.21 56.90 36.96 43.82 43.82 43.82
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 196 267.6 443.3 660.1 829.3 950.8 1,097 1,310
EBITDA 1 -63.54 147.5 278.9 315 426.2 553 688.7 832.3
EBIT 1 -67.61 144.3 275.9 267.5 337.6 473.6 614.8 803.8
Operating Margin -34.5% 53.91% 62.24% 40.53% 40.71% 49.81% 56.05% 61.36%
Earnings before Tax (EBT) 1 -72.25 129.3 248.5 248.9 348.3 470.7 608.2 789.4
Net income 1 -72.24 129.1 402.7 202.1 281.6 372.8 466.5 612.6
Net margin -36.86% 48.24% 90.84% 30.62% 33.96% 39.21% 42.53% 46.76%
EPS 2 -0.5000 0.9100 2.740 1.440 2.100 3.029 3.843 5.284
Free Cash Flow 1 -89.46 52.95 298 235.3 - 471 596 -
FCF margin -45.65% 19.79% 67.22% 35.65% - 49.54% 54.34% -
FCF Conversion (EBITDA) - 35.89% 106.84% 74.7% - 85.17% 86.54% -
FCF Conversion (Net income) - 41.02% 73.99% 116.41% - 126.33% 127.76% -
Dividend per Share - - - - - - - -
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 102 117.3 152.4 209 181.5 162.1 221 216 230 195.9 201.1 255.5 295.2 248.4 258.5
EBITDA 1 57.31 81.19 40.84 85.3 79.45 74.54 115.1 114.9 121.7 115.7 110.2 149.7 194.5 156.9 163.9
EBIT 1 56.53 75.67 34.06 83.29 74.51 53.8 94.46 88.28 101 95.54 90.13 134.3 153.5 139.8 148.8
Operating Margin 55.42% 64.52% 22.35% 39.86% 41.05% 33.18% 42.73% 40.86% 43.92% 48.78% 44.81% 52.56% 52.02% 56.28% 57.54%
Earnings before Tax (EBT) 1 54.81 74.41 30.01 73.71 70.79 52.24 93.16 101.8 101.2 96.03 89.07 131.6 154 140.6 151
Net income 1 66.77 60.11 22.68 61.63 57.7 39.62 74.75 81.84 85.39 76.82 71.24 105 122 112.6 121
Net margin 65.46% 51.25% 14.89% 29.49% 31.79% 24.43% 33.82% 37.88% 37.12% 39.22% 35.42% 41.07% 41.34% 45.35% 46.8%
EPS 2 0.4600 0.4300 0.1600 0.4400 0.4200 0.2900 0.5700 0.6100 0.6500 0.6000 0.5788 0.8450 0.9762 0.9333 0.9650
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/22/22 5/10/22 8/9/22 11/8/22 2/21/23 5/9/23 8/8/23 11/6/23 2/20/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 282 250 136 1,143 1,163 899 422 277
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) -4.444 x 1.691 x 0.4867 x 3.63 x 2.729 x 1.626 x 0.6126 x 0.3323 x
Free Cash Flow 1 -89.5 53 298 235 - 471 596 -
ROE (net income / shareholders' equity) -42.4% 106% 169% 110% 293% 169% 91.7% 82.5%
ROA (Net income/ Total Assets) -14.4% 22.5% 34.9% 13.7% 20.8% 26.7% 28.8% 29.6%
Assets 1 503.1 572.9 1,153 1,473 1,354 1,399 1,618 2,070
Book Value Per Share 2 0.6700 1.120 1.430 1.260 - 4.450 7.890 9.960
Cash Flow per Share 2 - 0.3900 2.040 1.710 - 3.620 - -
Capex 1 4.04 2.5 1.46 4.81 - 2 2 -
Capex / Sales 2.06% 0.94% 0.33% 0.73% - 0.21% 0.18% -
Announcement Date 2/24/20 2/23/21 2/22/22 2/21/23 2/20/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Halozyme Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
43.08 USD
Average target price
51.44 USD
Spread / Average Target
+19.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
+16.56% 5.58B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. HALO Stock
  4. Financials Halozyme Therapeutics, Inc.